Summary of Conference Call Notes Industry Overview - The conference focuses on the innovative pharmaceutical sector, particularly the PD-(L)1 Plus treatment landscape, which is becoming a competitive area for overseas pharmaceutical companies [1][2]. Key Insights and Arguments - **Market Performance**: The pharmaceutical sector has shown strong performance recently, with significant volatility in innovative drugs. The core stocks have remained relatively stable during adjustments, driven by short-term trading dynamics [3]. - **Investment Outlook**: There is a strong bullish sentiment towards the innovative drug market, supported by solid underlying logic and clear industry trends. Key innovative drug targets, especially those with BD expectations or PD-1 Plus logic, are expected to perform well even during market corrections [3]. - **Investment Strategy**: Four main investment lines are recommended: Chinese supermarkets, generic drug opportunities, re-evaluation of small-cap pipelines, and large overseas pharmaceuticals. The strategy includes a combination of buying and random rotation for explosive growth [3]. - **Focus Areas**: Attention is drawn to the PD-1 Plus logic, particularly the potential upgrade from PD-1/VEGF to PD-1/IL-2. Upcoming opportunities related to the ADA conference in late June and advancements in medical technology (brain-computer interfaces, rehabilitation robots, AI in healthcare) are highlighted [3]. - **2025 Outlook**: Optimism prevails for the pharmaceutical sector, with expectations of a structural bull market. Focus areas include innovative drugs, new technologies, and industry restructuring [3]. Clinical Data Insights - **Sinda's PD-1/IL-2 (IBI363) Data**: - In non-small cell lung cancer (wild-type), the 1-1.5 mg/kg group showed an ORR of 25.9% and a median OS of 15.3 months, while the 3 mg/kg group had an ORR of 36.7% and a median PFS of 9.3 months, suggesting a potential median OS of 20-25+ months [3]. - In lung adenocarcinoma (wild-type), the low-dose group (0.6/1.5 mg/kg) had an ORR of 13.08% and a median PFS of 2.7 months, while the high-dose group (3 mg/kg) showed an ORR of 24% and a median PFS of 5.6 months, with a potential median OS of 25-30 months [3]. - The data indicates a high OS/PFS ratio, particularly in lung adenocarcinoma, which is rare and suggests a potential to limit metastatic tumors [3][4]. Competitive Landscape - **PD-1 Plus Market**: The PD-(L)1 market is substantial, estimated at around $40 billion, and is undergoing innovation. Major multinational corporations are actively investing in PD-1 Plus, contributing to rising upfront payments in business development [6]. - **Key Companies to Watch**: Notable companies in the PD-1 Plus space include Sinda, Hengrui, BeiGene, Kangfang Biotech, Rongchang Biotech, Aosaikang, and Zhimeng Junshi [6]. Sector-Specific Updates - **Innovative Drugs**: The index for innovative drugs rose by 0.34% last week, with a positive long-term outlook driven by clinical data and business development catalysts [6]. - **Generic Drugs**: The index increased by 1.69%, outperforming the pharmaceutical index. Key events include the approval of a compound release tablet by Shenda and the acceptance of a conditional listing application for a hemophilia drug [6]. - **Traditional Chinese Medicine & Pharmacies**: The Chinese medicine index rose by 0.39%, while pharmacies increased by 1.67%, with a focus on policy impacts and operational strategies [6]. - **Medical Devices**: The medical device index rose by 1.11%, with attention on equipment updates and market recovery [6]. - **Life Sciences**: The life sciences sector saw an average increase of 1.47%, with a focus on operational recovery and investment trends [6]. Additional Considerations - **Stock Selection**: Emphasis on companies with clean shareholding structures, low stock prices, and positive future operational trends. Monitoring monthly operational data and overall consumption data is crucial [7].

Investment Rating - The investment rating for the industry is "Positive" and is maintained [9] Core Insights - CEACAM5 is a member of the immunoglobulin superfamily adhesion molecules, highly expressed in various malignancies such as colorectal cancer, gastrointestinal cancer, and lung cancer, playing a significant role in tumor occurrence, invasion, and metastasis [2][6][18] - With the first clinical trial of SAR408701 by Sanofi entering Phase III, CEACAM5 ADC has become a popular development direction for targeted therapy drugs [2][28] - Currently, there are 8 CEACAM5-targeted ADCs in development globally, with 6 having entered clinical stages, showcasing a trend of diverse technological pathways and distinctive mechanisms among major pharmaceutical companies [2][8] Summary by Sections CEACAM5 as a Target - CEACAM5 is recognized as a high-expression tumor target, with its drug development potential accelerating due to the emergence of various therapeutic approaches, including ADCs, monoclonal antibodies, bispecific antibodies, CAR-T cell therapies, and therapeutic vaccines [6][28] CEACAM5 ADC Development - The heat around CEACAM5 ADC is rising, with the design of effective connections being key to overcoming challenges related to its weak internalization capacity [7][32] - The development focus is shifting towards optimizing linkers and payload systems to enhance stability and ensure precise release in the tumor microenvironment [7][32] Competitive Landscape - Major pharmaceutical companies are actively positioning themselves in the CEACAM5 ADC space, with notable developments from Sanofi, Merck, Innovent, and BeiGene, each showcasing unique design strategies and therapeutic potentials [8][50][58][61] - Sanofi's SAR408701, despite facing setbacks, continues to explore its potential in other cancer types, while Merck's M9140 is the first to utilize a topoisomerase I inhibitor in this context [8][50] Investment Perspective - The report suggests that the ongoing innovation in drug development, particularly in the context of CEACAM5-targeted therapies, presents significant investment opportunities, especially for companies with strong cash flows and innovative capabilities [64]

Group 1 - The core viewpoint of the news is the performance and holdings of the Industrial and Commercial Bank of China Medical Healthcare Stock Fund, which has shown positive returns in various time frames [1] - The latest net value of the fund is 2.7270 yuan, with a growth of 1.79% [1] - The fund's performance over the past month has yielded a return of 8.91%, ranking 96 out of 1025 in its category [1] - Over the last six months, the fund has achieved a return of 13.01%, ranking 146 out of 989 [1] - Year-to-date, the fund has returned 19.66%, ranking 96 out of 999 [1] Group 2 - The top ten holdings of the fund account for a total of 39.79%, with significant positions in companies such as Heng Rui Pharmaceutical (8.90%) and WuXi AppTec (5.12%) [1] - The fund was established on November 18, 2014, and as of March 31, 2025, it has a total scale of 2.724 billion yuan [1] - The fund is managed by Zhao Bei and Ding Yang, both of whom have extensive experience in the healthcare sector [2]

Summary of the Conference Call for BeiGene Company Overview - **Company**: BeiGene - **Industry**: Biotechnology, specifically focused on innovative drug development Key Points and Arguments 1. **Profitability Outlook**: BeiGene expects to achieve positive operating profit under GAAP by 2025, with a projected net profit margin exceeding 10% in the next 3-5 years, highlighting the importance of sustainable profitability [2][5][8] 2. **Core Product Performance**: The sales of the core product, Zanubrutinib, are anticipated to reach $3.7 billion in 2025, representing a 50% year-over-year growth. The market is particularly focused on the future sales strategy and value changes of this product [2][5][6] 3. **Competitive Landscape**: The impact of Pirtobrutinib on Zanubrutinib is considered limited, with new patient share exceeding 50%. Future expectations suggest that the market share could reach $7.5 billion [2][5][6] 4. **Pipeline Development**: In the hematology field, BeiGene has multiple products including BCL-2 and BTK inhibitors, with BCL-2 inhibitors rapidly advancing for frontline CLL indications, potentially becoming significant global treatments [2][7] 5. **Solid Tumor Research**: Data on CDK4 inhibitors will be shared on June 26, which may establish their best-in-class potential, showcasing the company's strong early-stage research capabilities [2][7] 6. **Stock Performance**: Since July 2024, BeiGene's stock has performed strongly, with expectations of profitability under Non-GAAP measures in 2025, boosting market confidence [2][8] 7. **Short-term Catalysts**: The upcoming R&D day on June 26 is expected to be a catalyst for short-term performance, with anticipated data on CDK4 inhibitors and possibly other surprise data [3][4][9] Additional Important Insights - **Sales Growth Trends**: Historically, the second quarter has shown the steepest sales growth for Zanubrutinib in the U.S., and this trend is expected to continue in 2025 [4][9] - **Clinical Trials**: The company plans to initiate two Phase III clinical trials, including a head-to-head comparison with a non-covalent BTK inhibitor, indicating strong global clinical operational capabilities [6][7] - **Market Positioning**: BeiGene is positioned as a significant representative in the Chinese innovative drug sector, driven by the rapid growth of Zanubrutinib and advancements in major indications [2][8]

Investment Rating - The report suggests a positive outlook for the pharmaceutical sector, indicating that the industry is expected to experience a sustained recovery and structural opportunities remain available [5][41]. Core Insights - The 2025 ASCO conference highlighted a record number of domestic new drug entries, with 74 abstracts accepted, including 34 oral presentations and 32 rapid oral presentations, marking a significant increase from 55 entries in 2024 [7][11]. - Several domestic innovative drugs demonstrated promising clinical data, particularly in oncology, with notable advancements in treatments for advanced non-small cell lung cancer, colorectal cancer, and pancreatic cancer [11][12][15]. - The pharmaceutical industry has underperformed compared to the CSI 300 index, with a rolling P/E ratio of 34.47 compared to 12.56 for the CSI 300, indicating a premium of 174.35% over the index [20][41]. Monthly Policy and Industry Updates - The ASCO 2025 conference showcased a record number of domestic new drugs, with significant clinical data released that attracted market attention [7][11]. - Multiple domestic drugs reported impressive results, particularly in cancer treatment, with specific drugs showing superior efficacy compared to existing therapies [11][12][15]. Industry Data Dynamics - The pharmaceutical sector has shown weaker performance compared to the CSI 300 index, with a decline of 14.00% in the SW pharmaceutical and biological index from early 2023 to June 5, 2025, while the CSI 300 index increased by 0.15% [20]. - The revenue growth of the pharmaceutical manufacturing industry has slowed due to the pandemic's impact, but it continues to grow faster than GDP [23]. - Outpatient expenses have risen due to the pandemic, while inpatient costs have been effectively controlled [26]. Investment Recommendations - The report emphasizes the potential for growth in the pharmaceutical sector, particularly in innovative drugs and their supply chains, as well as in medical devices and third-party medical testing [41][42]. - Specific companies are highlighted for their strong positions in the market, including those involved in innovative drug development and medical device manufacturing [41][42][43].

Core Viewpoint - The recent tightening of U.S. regulatory policies and escalating geopolitical tensions have reignited discussions about the return of Chinese concept stocks (Chinext stocks) to Hong Kong, with the Hong Kong government implementing measures to solidify its position as the preferred destination for these listings [1][7]. Group 1: Market Trends - Since the reform of the listing system in 2018, 33 Chinese concept companies have chosen to list in Hong Kong, accounting for over 70% of the total market capitalization of all Chinese concept stocks [3][4]. - The trend shows that large-cap leading companies are often the first to initiate the return process, with 12 companies having a market capitalization exceeding 1 trillion HKD [4][5]. - As of June 5, 2023, 73% of the top quartile of Chinese concept stocks have achieved a dual listing, with 45% completing a primary dual listing and 26% achieving a secondary listing in Hong Kong [5]. Group 2: Industry Distribution - Chinese concept stocks are primarily concentrated in three sectors: new consumption, technology, and mid-to-high-end manufacturing, with retail accounting for 54% of the new consumption sector [6]. - The valuation discount previously faced by Chinese concept stocks in the Hong Kong market has been gradually alleviated due to increased market activity since last year [6]. Group 3: Government Initiatives - The Hong Kong government is committed to making the region the preferred destination for the return of Chinese concept stocks, with proactive measures being taken by the Securities and Futures Commission and the Hong Kong Stock Exchange [7][8]. - Hong Kong's financial market is characterized by its dual attributes of global capital allocation and local market familiarity, making it an attractive option for Chinese companies looking to return [8]. Group 4: Advantages of Returning to Hong Kong - The flexibility and inclusiveness of Hong Kong's regulatory environment provide significant advantages for Chinese concept stocks, including the ability to retain VIE structures and tax incentives [8]. - Hong Kong serves as a "safe haven," allowing for effective liquidity support from mainland funds while facilitating international capital inflows [7][8].

Group 1 - Hansoh Pharmaceutical granted Regeneron Pharmaceuticals exclusive overseas licensing for its GLP-1/GIP dual receptor agonist HS-20094, which has completed multiple Phase II clinical trials and is currently in Phase III trials in China [1][2] - The licensing agreement includes an upfront payment of $80 million, potential milestone payments of up to $1.93 billion, and double-digit royalties on future sales [2][3] - Recent licensing deals by Chinese pharmaceutical companies indicate a growing trend, with 33 license-out transactions completed in Q1 2025, totaling $36.633 billion, a year-on-year increase of approximately 258% [1][6] Group 2 - The licensing deal with Pfizer for the PD-1/VEGF dual antibody SSGJ-707 includes a record upfront payment of $1.25 billion, with potential milestone payments reaching $4.8 billion [3] - Other companies, such as Sinovant and Ansai, have also announced licensing agreements, indicating a robust market for Chinese pharmaceutical innovations [3][4] - The 2025 ASCO annual meeting showcased over 70 original research results from China, highlighting the international competitiveness of Chinese innovative drugs [4][5] Group 3 - The overall trend shows that Chinese innovative drugs are gaining global value, with a significant increase in licensing transactions and amounts [6][7] - The pharmaceutical industry is expected to see steady recovery, driven by the growing demand for innovative therapies and the improvement in the quality and quantity of domestic innovative drugs [7]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年5月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 百濟神州有限公司 (根據瑞士法律註冊成立的公司) 呈交日期: 2025年6月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06160 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 9,500,000,000 | USD | 0.0001 | USD | | 950,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 9,500,000,000 | USD | 0.0001 | USD | | 950,000 | 備註： | ...

Group 1 - The pharmaceutical sector has recently experienced a significant pullback, with the innovative drug concept seeing a net outflow of nearly 2.5 billion yuan in A-shares [1] - The Tianhong Innovative Drug ETF (517380) reached a new high for the year before experiencing a substantial decline, dropping 2.75% with a trading volume of 22 million yuan, and most constituent stocks fell nearly 5% [1] - The Tianhong Innovative Drug ETF is the only product tracking the Hang Seng-Hu-Shen-Hong Kong Innovative Drug Selected 50 Index, which includes leading innovative drug companies from the three markets [1] Group 2 - Dongwu Securities predicts that 2025 will mark the explosive growth of China's innovative drug industry, driven by three core factors: significant BD transactions, profitability turning points for leading companies, and an improving policy environment [2] - Guosheng Securities acknowledges short-term trading pullback risks but emphasizes the solid underlying logic and clear trends in the innovative drug sector, maintaining a positive outlook for the innovative drug bull market [2] - The market size of China's innovative drugs is expected to exceed 2 trillion yuan by 2030, with a compound annual growth rate of 24.1% [2]

Group 1 - Over 200 foreign institutions have conducted research on A-share listed companies since May, totaling more than 500 investigations, with a focus on hard technology sectors such as electronic devices and integrated circuits [1] - Notable foreign institutions involved in the research include Goldman Sachs, Fidelity, BlackRock, UBS, Allianz, and Point72, with companies like Aopu Technology, Lanke Technology, Hudian Co., and Aobi Zhongguang attracting over 30 foreign institution investigations each [1] - Point72, referred to as "Wall Street's craziest money-making machine," led the research activities with 17 investigations, focusing on companies such as Huace Testing, Miaoke Landuo, and Ruixin Micro [1] Group 2 - In addition to electronic devices and integrated circuits, sectors such as healthcare, industrial machinery, and electronic components have also garnered significant attention from foreign institutions, with industry leaders like BeiGene, Huichuan Technology, New Industry, and Shenzhen South Circuit receiving the most investigations [2] - Multiple foreign giants believe that the A-share market presents abundant investment opportunities, particularly in the technology growth sector, with Morgan Stanley highlighting key areas such as technology growth, Chinese manufacturing, and new consumption as worthy of attention [3] - Morgan Asset Management is optimistic about sectors including leading automotive manufacturers and components, AI-related industries, robotics, trendy toys, and pet-related businesses [3]